Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of an anti–human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models

Blood (2023) 142 (12): 1071–1081.

https://doi.org/10.1182/blood.2023020005

Published: 2023

Includes: Supplemental data

Journal Articles

Calculation of Metabolic Tumor Volume in Diffuse Large B-Cell Lymphoma Using a Deep Learning-Aided Automated Method

Juan Pablo Alderuccio, Russ A. Kuker, David Lehmkuhl, Deukwoo Kwon, Andrea Cordoba, Weizhao Zhao, Izidore S. Lossos, Craig H. Moskowitz, Fei Yang

Blood (2022) 140 (Supplement 1): 4972–4973.

https://doi.org/10.1182/blood-2022-165676

Published: 2022

Journal Articles

Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Blood (2022) 140 (Supplement 1): 6650–6652.

https://doi.org/10.1182/blood-2022-162758

Published: 2022

Journal Articles

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Blood (2022) 139 (8): 1208–1221.

https://doi.org/10.1182/blood.2021011354

Published: 2022

Includes: Supplemental data

Journal Articles

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Blood (2021) 138 (Supplement 1): 226.

https://doi.org/10.1182/blood-2021-152838

Published: 2021

Journal Articles

Socioeconomic Disparities in Diagnostic Testing Among Patients with Diffuse Large B-Cell Lymphoma in the US

Fei Yang, MBBS,MMSc,PhD, Anup Abraham, MPH, Ju Zhang, MSPH, PhD, Yan Xiao, MD PhD, Richard D. Hammer, MD, Donald C. Doll, MD, Matthew S. Prime, BSc, MBBS, MRCS, PhD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-134687

Published: 2020

Journal Articles

Identification and Reporting of Cell of Origin, Double-/Triple-Hit and Double Expressor Lymphoma in a Real-World Cohort of Diffuse Large B-Cell Lymphoma Patients

Fei Yang, MBBS,MMSc,PhD, Anup Abraham, MPH, Ju Zhang, MSPH, PhD, Yan Xiao, MD PhD, Richard D. Hammer, MD, Donald C. Doll, MD, Matthew S. Prime, BSc, MBBS, MRCS, PhD

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-134674

Published: 2020

Journal Articles

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 2145.

https://doi.org/10.1182/blood-2019-131253

Published: 2019

Journal Articles

Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 373.

https://doi.org/10.1182/blood-2019-131925

Published: 2019

Journal Articles

Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice

Pedro G Vianna, BSc,MD, Richard D. Press, MD PhD, Henning Stehr, PhD, Fei Yang, MD, Linda Gojenola, James L Zehnder, Jason Gotlib, MD MS

Blood (2019) 134 (Supplement_1): 1408.

https://doi.org/10.1182/blood-2019-124445

Published: 2019

Journal Articles

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Daniel Bottomly, Nicola Long, Fei Yang, MD, Tiffany Lee, MD, Uma Borate, MD, Beth Wilmot, PhD, Adam S DuVall, MD, Andrea Monteblanco, BS, Karina Thiel-Klare, Gabby Dewson, BA, Richard D. Press, MD PhD, Cristina E. Tognon, Brian J. Druker, Jeffrey W. Tyner, Shannon K. McWeeney, PhD, Anupriya Agarwal, PhD

Blood (2019) 134 (Supplement_1): 1407.

https://doi.org/10.1182/blood-2019-132224

Published: 2019

Journal Articles

Mutations Modifying Risk in NPM1+ AML

Jessica Leonard, MD, Jennifer Dunlap, MD, Tanaya L Neff, Andrea Warrick, Fei Yang, Richard D. Press, MD PhD, Brian J. Druker, MD, Elie Traer, MD, PhD

Blood (2015) 126 (23): 2592.

https://doi.org/10.1182/blood.V126.23.2592.2592

Published: 2015

Journal Articles

Genetic Deletion of CCRL2 Impairs Macrophage Accumulation in Arterial Intima and Attenuates Atherosclerotic Plaque Development

Yiren Cao, MD, Fei Yang, MS, Chaojun Tang, PhD, Shuhong Hu, MS, Brian Anthony Zabel, PhD, Li Zhu, MD PhD

Blood (2015) 126 (23): 2239.

https://doi.org/10.1182/blood.V126.23.2239.2239

Published: 2015

Journal Articles

Thromboxane A 2 Signaling Regulates Heterogeneous Platelet Activation Following Laser-Induced Injury In Mouse Cremaster Arterioles

Jian Shen, BS, Fei Yang, MS, Yujun Shen, PhD, Ying Yu, MD, PhD, Timothy J. Stalker, PhD, Li Zhu, MD, PhD

Blood (2013) 122 (21): 1055.

https://doi.org/10.1182/blood.V122.21.1055.1055

Published: 2013

Journal Articles

TNFα facilitates clonal expansion of JAK2 V617F positive cells in myeloproliferative neoplasms

Angela G. Fleischman, Karl J. Aichberger, Samuel B. Luty, Thomas G. Bumm, Curtis L. Petersen, Shirin Doratotaj, Kavin B. Vasudevan, Dorian H. LaTocha, Fei Yang, Richard D. Press, Marc M. Loriaux, Heike L. Pahl, Richard T. Silver, Anupriya Agarwal, Thomas O'Hare, Brian J. Druker, Grover C. Bagby, Michael W. Deininger

Blood (2011) 118 (24): 6392–6398.

https://doi.org/10.1182/blood-2011-04-348144

Published: 2011

Includes: Supplemental data

Journal Articles

ERG, BAALC, and MN1 RNA Levels Are Correlatively Over-Expressed, and Relate to Risk-Defining Prognostic Mutations in Intermediate-Risk Acute Myeloid Leukemia

Fei Yang, Franklin Moore, M.D., Ph.D., Dean Westberry, Miriam Hough, Julie Partain, William H Fleming, MD, PhD, Tibor Kovacsovics, MD, Richard D. Press, MD, PhD

Blood (2011) 118 (21): 1471.

https://doi.org/10.1182/blood.V118.21.1471.1471

Published: 2011

Journal Articles

The BCR-ABL 35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Thomas O'Hare, Matthew S. Zabriskie, Christopher A. Eide, Anupriya Agarwal, Lauren T. Adrian, Huihong You, Amie S. Corbin, Fei Yang, Richard D. Press, Victor M. Rivera, Julie Toplin, Stephane Wong, Michael W. Deininger, Brian J. Druker

Blood (2011) 118 (19): 5250–5254.

https://doi.org/10.1182/blood-2011-05-349191

Published: 2011

Includes: Supplemental data

Journal Articles

Comparison of Different Laboratory Methods for Quantification of BCR-ABL Kinase Domain Mutations In CML Patients Undergoing Tyrosine Kinase Inhibitor Therapy

Richard D. Press, MD, PhD, Fei Yang

Blood (2010) 116 (21): 2760.

https://doi.org/10.1182/blood.V116.21.2760.2760

Published: 2010

NARROW

Safety and efficacy of an anti–human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models

Calculation of Metabolic Tumor Volume in Diffuse Large B-Cell Lymphoma Using a Deep Learning-Aided Automated Method

Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Socioeconomic Disparities in Diagnostic Testing Among Patients with Diffuse Large B-Cell Lymphoma in the US

Identification and Reporting of Cell of Origin, Double-/Triple-Hit and Double Expressor Lymphoma in a Real-World Cohort of Diffuse Large B-Cell Lymphoma Patients

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial

Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Mutations Modifying Risk in NPM1+ AML

Genetic Deletion of CCRL2 Impairs Macrophage Accumulation in Arterial Intima and Attenuates Atherosclerotic Plaque Development

Thromboxane A 2 Signaling Regulates Heterogeneous Platelet Activation Following Laser-Induced Injury In Mouse Cremaster Arterioles

TNFα facilitates clonal expansion of JAK2 V617F positive cells in myeloproliferative neoplasms

ERG, BAALC, and MN1 RNA Levels Are Correlatively Over-Expressed, and Relate to Risk-Defining Prognostic Mutations in Intermediate-Risk Acute Myeloid Leukemia

The BCR-ABL 35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Comparison of Different Laboratory Methods for Quantification of BCR-ABL Kinase Domain Mutations In CML Patients Undergoing Tyrosine Kinase Inhibitor Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only